Proteinopathy Explained

In medicine, proteinopathy ([''pref''. protein]; -pathy [''suff''. disease]; proteinopathies pl.; proteinopathic adj), or proteopathy, protein conformational disorder, or protein misfolding disease, is a class of diseases in which certain proteins become structurally abnormal, and thereby disrupt the function of cells, tissues and organs of the body.[1] [2] Often the proteins fail to fold into their normal configuration; in this misfolded state, the proteins can become toxic in some way (a toxic gain-of-function) or they can lose their normal function.[3] The proteinopathies include such diseases as Creutzfeldt–Jakob disease (and a variant associated with mad cow disease) and other prion diseases, Alzheimer's disease, Parkinson's disease, amyloidosis, multiple system atrophy, and a wide range of other disorders.[4] [5] [6] [7] [8] The term proteopathy was first proposed in 2000 by Lary Walker and Harry LeVine.[9]

The concept of proteopathy can trace its origins to the mid-19th century, when, in 1854, Rudolf Virchow coined the term amyloid ("starch-like") to describe a substance in cerebral corpora amylacea that exhibited a chemical reaction resembling that of cellulose. In 1859, Friedreich and Kekulé demonstrated that, rather than consisting of cellulose, "amyloid" actually is rich in protein.[10] Subsequent research has shown that many different proteins can form amyloid, and that all amyloids show birefringence in cross-polarized light after staining with the dye Congo red, as well as a fibrillar ultrastructure when viewed with an electron microscope.[10] However, some proteinaceous lesions lack birefringence and contain few or no classical amyloid fibrils, such as the diffuse deposits of amyloid beta (Aβ) protein in the brains of people with Alzheimer's.[11] Furthermore, evidence has emerged that small, non-fibrillar protein aggregates known as oligomers are toxic to the cells of an affected organ, and that amyloidogenic proteins in their fibrillar form may be relatively benign.[12] [13]

Pathophysiology

In most, if not all proteinopathies, a change in the 3-dimensional folding conformation increases the tendency of a specific protein to bind to itself.[5] In this aggregated form, the protein is resistant to clearance and can interfere with the normal capacity of the affected organs. In some cases, misfolding of the protein results in a loss of its usual function. For example, cystic fibrosis is caused by a defective cystic fibrosis transmembrane conductance regulator (CFTR) protein,[3] and in amyotrophic lateral sclerosis / frontotemporal lobar degeneration (FTLD), certain gene-regulating proteins inappropriately aggregate in the cytoplasm, and thus are unable to perform their normal tasks within the nucleus.[14] [15] Because proteins share a common structural feature known as the polypeptide backbone, all proteins have the potential to misfold under some circumstances.[16] However, only a relatively small number of proteins are linked to proteopathic disorders, possibly due to structural idiosyncrasies of the vulnerable proteins. For example, proteins that are normally unfolded or relatively unstable as monomers (that is, as single, unbound protein molecules) are more likely to misfold into an abnormal conformation.[5] [16] [17] In nearly all instances, the disease-causing molecular configuration involves an increase in beta-sheet secondary structure of the protein.[5] [16] [18] [19] [20] The abnormal proteins in some proteopathies have been shown to fold into multiple 3-dimensional shapes; these variant, proteinaceous structures are defined by their different pathogenic, biochemical, and conformational properties.[21] They have been most thoroughly studied with regard to prion disease, and are referred to as protein strains.[22] [23]

The likelihood that proteinopathy will develop is increased by certain risk factors that promote the self-assembly of a protein. These include destabilizing changes in the primary amino acid sequence of the protein, post-translational modifications (such as hyperphosphorylation), changes in temperature or pH, an increase in production of a protein, or a decrease in its clearance.[1] [5] [16] Advancing age is a strong risk factor,[1] as is traumatic brain injury.[24] [25] In the aging brain, multiple proteopathies can overlap.[26] For example, in addition to tauopathy and Aβ-amyloidosis (which coexist as key pathologic features of Alzheimer's disease), many Alzheimer patients have concomitant synucleinopathy (Lewy bodies) in the brain.[27]

It is hypothesized that chaperones and co-chaperones (proteins that assist protein folding) may antagonize proteotoxicity during aging and in protein misfolding-diseases to maintain proteostasis.[28] [29] [30]

Seeded induction

Some proteins can be induced to form abnormal assemblies by exposure to the same (or similar) protein that has folded into a disease-causing conformation, a process called 'seeding' or 'permissive templating'.[31] [32] In this way, the disease state can be brought about in a susceptible host by the introduction of diseased tissue extract from an affected donor. The best known forms of inducible proteopathy are prion diseases,[33] which can be transmitted by exposure of a host organism to purified prion protein in a disease-causing conformation.[34] [35] There is now evidence that other proteinopathies can be induced by a similar mechanism, including Aβ amyloidosis, amyloid A (AA) amyloidosis, and apolipoprotein AII amyloidosis,[32] [36] tauopathy,[37] synucleinopathy,[38] [39] [40] [41] and the aggregation of superoxide dismutase-1 (SOD1),[42] [43] polyglutamine,[44] [45] and TAR DNA-binding protein-43 (TDP-43).[46]

In all of these instances, an aberrant form of the protein itself appears to be the pathogenic agent. In some cases, the deposition of one type of protein can be experimentally induced by aggregated assemblies of other proteins that are rich in β-sheet structure, possibly because of structural complementarity of the protein molecules. For example, AA amyloidosis can be stimulated in mice by such diverse macromolecules as silk, the yeast amyloid Sup35, and curli fibrils from the bacterium Escherichia coli.[47] AII amyloid can be induced in mice by a variety of β-sheet rich amyloid fibrils,[48] and cerebral tauopathy can be induced by brain extracts that are rich in aggregated Aβ.[49] There is also experimental evidence for cross-seeding between prion protein and Aβ.[50] In general, such heterologous seeding is less efficient than is seeding by a corrupted form of the same protein.

List of proteinopathies

ProteinopathyMajor aggregating protein
Alzheimer's disease[51] Amyloid β peptide (Aβ); Tau protein (see tauopathies)
Cerebral β-amyloid angiopathy[52] Amyloid β peptide (Aβ)
Retinal ganglion cell degeneration in glaucoma[53] Amyloid β peptide (Aβ)
Prion diseases (multiple)[54] Prion protein
Parkinson's disease and other synucleinopathies (multiple)[55] α-Synuclein
Tauopathies (multiple)[56] Microtubule-associated protein tau (Tau protein)
Frontotemporal lobar degeneration (FTLD) (Ubi+, Tau-)[57] TDP-43
FTLD–FUS[58] Fused in sarcoma (FUS) protein
Amyotrophic lateral sclerosis (ALS)[59] [60] Superoxide dismutase, TDP-43, FUS, C9ORF72, ubiquilin-2 (UBQLN2)
Huntington's disease and other trinucleotide repeat disorders (multiple)[61] [62] Proteins with tandem glutamine expansions
Familial British dementia[63] ABri
Familial Danish dementia[64] ADan
Hereditary cerebral hemorrhage with amyloidosis (Icelandic) (HCHWA-I)[65] Cystatin C
CADASIL[66] Notch3
Alexander disease[67] Glial fibrillary acidic protein (GFAP)
Pelizaeus-Merzbacher diseaseproteolipid protein (PLP)
Seipinopathies[68] Seipin
Familial amyloidotic neuropathy, Senile systemic amyloidosisTransthyretin[69]
Serpinopathies (multiple)[70] Serpins
AL (light chain) amyloidosis (primary systemic amyloidosis)Monoclonal immunoglobulin light chains[71]
AH (heavy chain) amyloidosisImmunoglobulin heavy chains[72]
AA (secondary) amyloidosisAmyloid A protein[73]
Type II diabetes[74] Islet amyloid polypeptide (IAPP; amylin)
Aortic medial amyloidosisMedin (lactadherin)[75]
ApoAI amyloidosisApolipoprotein AI[76]
ApoAII amyloidosisApolipoprotein AII[77]
ApoAIV amyloidosisApolipoprotein AIV[78]
Familial amyloidosis of the Finnish type (FAF)Gelsolin[79]
Lysozyme amyloidosisLysozyme[80]
Fibrinogen amyloidosisFibrinogen[81]
Dialysis amyloidosisBeta-2 microglobulin[82]
Inclusion body myositis/myopathy[83] Amyloid β peptide (Aβ)
Cataracts[84] Crystallins
Retinitis pigmentosa with rhodopsin mutations[85] rhodopsin
Medullary thyroid carcinomaCalcitonin[86]
Cardiac atrial amyloidosisAtrial natriuretic factor[87]
Pituitary prolactinomaProlactin[88]
Hereditary lattice corneal dystrophyKeratoepithelin[89]
Cutaneous lichen amyloidosis[90] Keratins
Mallory bodies[91] Keratin intermediate filament proteins
Corneal lactoferrin amyloidosisLactoferrin[92]
Pulmonary alveolar proteinosisSurfactant protein C (SP-C)[93]
Odontogenic (Pindborg) tumor amyloidOdontogenic ameloblast-associated protein[94]
Seminal vesicle amyloidSemenogelin I[95]
Apolipoprotein C2 amyloidosisApolipoprotein C2 (ApoC2)[96]
Apolipoprotein C3 amyloidosisApolipoprotein C3 (ApoC3)[97]
Lect2 amyloidosisLeukocyte chemotactic factor-2 (Lect2)[98]
Insulin amyloidosisInsulin[99]
Galectin-7 amyloidosis (primary localized cutaneous amyloidosis)Galectin-7 (Gal7)[100]
Corneodesmosin amyloidosisCorneodesmosin[101]
Enfuvirtide amyloidosis[102] Enfuvirtide[103]
Cystic fibrosis[104] cystic fibrosis transmembrane conductance regulator (CFTR) protein
Sickle cell disease[105] Hemoglobin
Plasma cell dyscrasias (monoclonal gammopathies) gamma globulin
Exfoliation syndrome[106] aka pseudoexfoliation syndromeaggregated fibrillar material esp. LOXL1

Management

The development of effective treatments for many proteopathies has been challenging.[107] [108] Because the proteopathies often involve different proteins arising from different sources, treatment strategies must be customized to each disorder; however, general therapeutic approaches include maintaining the function of affected organs, reducing the formation of the disease-causing proteins, preventing the proteins from misfolding and/or aggregating, or promoting their removal.[109] [107] [110] For example, in Alzheimer's disease, researchers are seeking ways to reduce the production of the disease-associated protein Aβ by inhibiting the enzymes that free it from its parent protein.[108] Another strategy is to use antibodies to neutralize specific proteins by active or passive immunization.[111] In some proteopathies, inhibiting the toxic effects of protein oligomers might be beneficial.[112]

For example, Amyloid A (AA) amyloidosis can be reduced by treating the inflammatory state that increases the amount of the protein in the blood (referred to as serum amyloid A, or SAA). In immunoglobulin light chain amyloidosis (AL amyloidosis), chemotherapy can be used to lower the number of the blood cells that make the light chain protein that forms amyloid in various bodily organs.[113] Transthyretin (TTR) amyloidosis (ATTR) results from the deposition of misfolded TTR in multiple organs.[114] Because TTR is mainly produced in the liver, TTR amyloidosis can be slowed in some hereditary cases by liver transplantation.[115] TTR amyloidosis also can be treated by stabilizing the normal assemblies of the protein (called tetramers because they consist of four TTR molecules bound together). Stabilization prevents individual TTR molecules from escaping, misfolding, and aggregating into amyloid.[116] [117]

Several other treatment strategies for proteopathies are being investigated, including small molecules and biologic medicines such as small interfering RNAs, antisense oligonucleotides, peptides, and engineered immune cells.[116] [113] [118] [119] In some cases, multiple therapeutic agents may be combined to improve effectiveness.[113] [120]

See also

External links

Notes and References

  1. Walker LC, LeVine H . The cerebral proteopathies . Neurobiology of Aging . 21 . 4 . 559–61 . 2000 . 10924770 . 10.1016/S0197-4580(00)00160-3 . 54314137 .
  2. Walker LC, LeVine H . The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly . Molecular Neurobiology . 21 . 1–2 . 83–95 . 2000 . 11327151 . 10.1385/MN:21:1-2:083 . 32618330 .
  3. Luheshi LM, Crowther DC, Dobson CM . Protein misfolding and disease: from the test tube to the organism . Current Opinion in Chemical Biology . 12 . 1 . 25–31 . February 2008 . 18295611 . 10.1016/j.cbpa.2008.02.011 .
  4. Chiti F, Dobson CM . Protein misfolding, functional amyloid, and human disease . Annual Review of Biochemistry . 75 . 1 . 333–66 . 2006 . 16756495 . 10.1146/annurev.biochem.75.101304.123901 . 23797549 .
  5. Carrell RW, Lomas DA . Conformational disease . Lancet . 350 . 9071 . 134–8 . July 1997 . 9228977 . 10.1016/S0140-6736(97)02073-4 . 39124185 .
  6. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD . A primer of amyloid nomenclature . Amyloid . 14 . 3 . 179–83 . September 2007 . 17701465 . 10.1080/13506120701460923 . 12480248 .
  7. Westermark GT, Fändrich M, Lundmark K, Westermark P . Noncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission . Cold Spring Harbor Perspectives in Medicine . 8 . 1 . a024323 . January 2018 . 28108533 . 10.1101/cshperspect.a024323 . 5749146 . free .
  8. Prusiner SB . Biology and genetics of prions causing neurodegeneration . Annual Review of Genetics . 47 . 601–23 . 2013 . 24274755 . 4010318 . 10.1146/annurev-genet-110711-155524 .
  9. Walker LC, LeVine H . The cerebral proteopathies . Neurobiology of Aging . 21 . 4 . 559–61 . 2000 . 10924770 . 10.1016/S0197-4580(00)00160-3 . 54314137 .
  10. Sipe JD, Cohen AS . Review: history of the amyloid fibril . Journal of Structural Biology . 130 . 2–3 . 88–98 . June 2000 . 10940217 . 10.1006/jsbi.2000.4221 .
  11. Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J . Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease . Journal of Neuropathology and Experimental Neurology . 57 . 7 . 674–83 . July 1998 . 9690671 . 10.1097/00005072-199807000-00004 . free .
  12. Glabe CG . Common mechanisms of amyloid oligomer pathogenesis in degenerative disease . Neurobiology of Aging . 27 . 4 . 570–5 . April 2006 . 16481071 . 10.1016/j.neurobiolaging.2005.04.017 . 32899741 .
  13. Gadad BS, Britton GB, Rao KS . Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide . Journal of Alzheimer's Disease . 24 . 223–32 . 2011 . Suppl 2 . 21460436 . 10.3233/JAD-2011-110182 .
  14. Ito D, Suzuki N . Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS . Neurology . 77 . 17 . 1636–43 . October 2011 . 21956718 . 3198978 . 10.1212/WNL.0b013e3182343365 .
  15. Book: Benjamin Wolozin

    . Wolozin B, Apicco D . GeNeDis 2014 . RNA Binding Proteins and the Genesis of Neurodegenerative Diseases . 822 . 11–5 . 2015 . 25416971 . 4694570 . 10.1007/978-3-319-08927-0_3 . 978-3-319-08926-3 . Advances in Experimental Medicine and Biology . Benjamin Wolozin .

  16. Dobson CM . Protein misfolding, evolution and disease . Trends in Biochemical Sciences . 24 . 9 . 329–32 . September 1999 . 10470028 . 10.1016/S0968-0004(99)01445-0 .
  17. Jucker M, Walker LC . Self-propagation of pathogenic protein aggregates in neurodegenerative diseases . Nature . 501 . 7465 . 45–51 . September 2013 . 24005412 . 3963807 . 10.1038/nature12481 . 2013Natur.501...45J .
  18. Selkoe DJ . Folding proteins in fatal ways . Nature . 426 . 6968 . 900–4 . December 2003 . 14685251 . 10.1038/nature02264 . 2003Natur.426..900S . 6451881 .
  19. . The amyloid state of proteins in human diseases . Cell . 148 . 6 . 1188–203 . March 2012 . 22424229 . 10.1016/j.cell.2012.02.022 . 3353745 .
  20. Röhr D, Boon BD . Label-free vibrational imaging of different Aβ plaque types in Alzheimer's disease reveals sequential events in plaque development . Acta Neuropathologica Communications . 8 . 1 . 222 . December 2020 . 33308303 . 10.1186/s40478-020-01091-5 . 7733282 . free .
  21. Walker LC . Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases . Annual Review of Genetics . 50 . 329–346 . November 2016 . 27893962 . 10.1146/annurev-genet-120215-034943 . 6690197 .
  22. Collinge J, Clarke AR . A general model of prion strains and their pathogenicity . Science . 318 . 5852 . 930–6 . November 2007 . 17991853 . 10.1126/science.1138718 . 2007Sci...318..930C . 8993435 .
  23. Colby DW, Prusiner SB . De novo generation of prion strains . Nature Reviews. Microbiology . 9 . 11 . 771–7 . September 2011 . 21947062 . 3924856 . 10.1038/nrmicro2650 .
  24. DeKosky ST, Ikonomovic MD, Gandy S . Traumatic brain injury--football, warfare, and long-term effects . The New England Journal of Medicine . 363 . 14 . 1293–6 . September 2010 . 20879875 . 10.1056/NEJMp1007051 .
  25. McKee AC, Stein TD, Kiernan PT, Alvarez VE . The neuropathology of chronic traumatic encephalopathy . Brain Pathology . 25 . 3 . 350–64 . May 2015 . 25904048 . 10.1111/bpa.12248 . 4526170 .
  26. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature . Journal of Neuropathology and Experimental Neurology . 71 . 5 . 362–81 . May 2012 . 22487856 . 10.1097/NEN.0b013e31825018f7 . 3560290 .
  27. Mrak RE, Griffin WS . Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer's disease . Neuropsychiatric Disease and Treatment . 3 . 5 . 619–25 . 2007 . 19300591 . 2656298 .
  28. Douglas PM, Summers DW, Cyr DM . Molecular chaperones antagonize proteotoxicity by differentially modulating protein aggregation pathways . Prion . 3 . 2 . 51–8 . 2009 . 19421006 . 2712599 . 10.4161/pri.3.2.8587 .
  29. Brehme M, Voisine C, Rolland T, Wachi S, Soper JH, Zhu Y, Orton K, Villella A, Garza D, Vidal M, Ge H, Morimoto RI . A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease . Cell Reports . 9 . 3 . 1135–50 . November 2014 . 25437566 . 4255334 . 10.1016/j.celrep.2014.09.042 .
  30. Brehme M, Voisine C . Model systems of protein-misfolding diseases reveal chaperone modifiers of proteotoxicity . Disease Models & Mechanisms . 9 . 8 . 823–38 . August 2016 . 27491084 . 5007983 . 10.1242/dmm.024703 .
  31. Hardy J . Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration . Biochemical Society Transactions . 33 . Pt 4 . 578–81 . August 2005 . 16042548 . 10.1042/BST0330578 .
  32. . Inducible proteopathies . Trends in Neurosciences . 29 . 8 . 438–43 . August 2006 . 16806508 . 10.1016/j.tins.2006.06.010 . 46630402 . 10725716 .
  33. Prusiner SB . Shattuck lecture--neurodegenerative diseases and prions . The New England Journal of Medicine . 344 . 20 . 1516–26 . May 2001 . 11357156 . 10.1056/NEJM200105173442006 . free .
  34. Zou WQ, Gambetti P . From microbes to prions the final proof of the prion hypothesis . Cell . 121 . 2 . 155–7 . April 2005 . 15851020 . 10.1016/j.cell.2005.04.002 . free .
  35. Ma J . The role of cofactors in prion propagation and infectivity . PLOS Pathogens . 8 . 4 . e1002589 . 2012 . 22511864 . 10.1371/journal.ppat.1002589 . 3325206 . free .
  36. . Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host . Science . 313 . 5794 . 1781–4 . September 2006 . 16990547 . 10.1126/science.1131864 . 2006Sci...313.1781M . 27127208 .
  37. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M . Transmission and spreading of tauopathy in transgenic mouse brain . Nature Cell Biology . 11 . 7 . 909–13 . July 2009 . 19503072 . 2726961 . 10.1038/ncb1901 .
  38. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ . Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein . Proceedings of the National Academy of Sciences of the United States of America . 106 . 31 . 13010–5 . August 2009 . 19651612 . 2722313 . 10.1073/pnas.0903691106 . free .
  39. Hansen C, Angot E, Bergström AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P . α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells . The Journal of Clinical Investigation . 121 . 2 . 715–25 . February 2011 . 21245577 . 3026723 . 10.1172/JCI43366 .
  40. Kordower JH, Dodiya HB, Kordower AM, Terpstra B, Paumier K, Madhavan L, Sortwell C, Steece-Collier K, Collier TJ . Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat . Neurobiology of Disease . 43 . 3 . 552–7 . September 2011 . 21600984 . 3430516 . 10.1016/j.nbd.2011.05.001 .
  41. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW . Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease . Nature Medicine . 14 . 5 . 504–6 . May 2008 . 18391962 . 10.1038/nm1747 . 11991816 .
  42. Chia R, Tattum MH, Jones S, Collinge J, Fisher EM, Jackson GS . Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis . PLOS ONE . 5 . 5 . e10627 . May 2010 . 20498711 . 2869360 . 10.1371/journal.pone.0010627 . Feany . Mel B. . free .
  43. Münch C, O'Brien J, Bertolotti A . Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells . Proceedings of the National Academy of Sciences of the United States of America . 108 . 9 . 3548–53 . March 2011 . 21321227 . 3048161 . 10.1073/pnas.1017275108 . 2011PNAS..108.3548M . free .
  44. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR . Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates . Nature Cell Biology . 11 . 2 . 219–25 . February 2009 . 19151706 . 2757079 . 10.1038/ncb1830 .
  45. Pearce MM, Kopito RR . Prion-Like Characteristics of Polyglutamine-Containing Proteins . Cold Spring Harbor Perspectives in Medicine . 8 . 2 . a024257 . February 2018 . 28096245 . 10.1101/cshperspect.a024257 . 5793740 .
  46. Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N . A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions . The Journal of Biological Chemistry . 286 . 21 . 18664–72 . May 2011 . 21454603 . 3099683 . 10.1074/jbc.M111.231209 . free .
  47. Lundmark K, Westermark GT, Olsén A, Westermark P . Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism . Proceedings of the National Academy of Sciences of the United States of America . 102 . 17 . 6098–102 . April 2005 . 15829582 . 1087940 . 10.1073/pnas.0501814102 . 2005PNAS..102.6098L . free .
  48. Fu X, Korenaga T, Fu L, Xing Y, Guo Z, Matsushita T, Hosokawa M, Naiki H, Baba S, Kawata Y, Ikeda S, Ishihara T, Mori M, Higuchi K . Induction of AApoAII amyloidosis by various heterogeneous amyloid fibrils . FEBS Letters . 563 . 1–3 . 179–84 . April 2004 . 15063745 . 10.1016/S0014-5793(04)00295-9 . free . 2004FEBSL.563..179F .
  49. . Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice . The American Journal of Pathology . 171 . 6 . 2012–20 . December 2007 . 18055549 . 2111123 . 10.2353/ajpath.2007.070403 .
  50. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, Soto C . Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases . The Journal of Neuroscience . 30 . 13 . 4528–35 . March 2010 . 20357103 . 2859074 . 10.1523/JNEUROSCI.5924-09.2010 .
  51. Jucker M, Walker LC . Self-propagation of pathogenic protein aggregates in neurodegenerative diseases . Nature . 501 . 7465 . 45–51 . September 2013 . 24005412 . 3963807 . 10.1038/nature12481 . 2013Natur.501...45J .
  52. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL . Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view . Journal of Neuropathology and Experimental Neurology . 62 . 9 . 885–98 . September 2003 . 14533778 . 10.1093/jnen/62.9.885 .
  53. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, Ferrari G, Russo-Marie F, Sillito AM, Cheetham ME, Moss SE, Fitzke FW, Cordeiro MF . Targeting amyloid-beta in glaucoma treatment . Proceedings of the National Academy of Sciences of the United States of America . 104 . 33 . 13444–9 . August 2007 . 17684098 . 1940230 . 10.1073/pnas.0703707104 . 2007PNAS..10413444G . free .
  54. Book: Prusiner. SB. Prion Biology and Diseases. 2004. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY. 0-87969-693-1. 2.
  55. Goedert M, Spillantini MG, Del Tredici K, Braak H . 100 years of Lewy pathology . Nature Reviews. Neurology . 9 . 1 . 13–24 . January 2013 . 23183883 . 10.1038/nrneurol.2012.242 . 12590215 .
  56. Clavaguera F, Hench J, Goedert M, Tolnay M . Invited review: Prion-like transmission and spreading of tau pathology . Neuropathology and Applied Neurobiology . 41 . 1 . 47–58 . February 2015 . 25399729 . 10.1111/nan.12197 . 45101893 .
  57. Mann DM, Snowden JS . Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype . Brain Pathology . 27 . 6 . 723–736 . November 2017 . 28100023 . 10.1111/bpa.12486 . 8029341 .
  58. Mann DM, Snowden JS . Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype . Brain Pathology . 27 . 6 . 723–736 . November 2017 . 28100023 . 10.1111/bpa.12486 . 8029341 .
  59. Grad LI, Fernando SM, Cashman NR . From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis . Neurobiology of Disease . 77 . 257–65 . May 2015 . 25701498 . 10.1016/j.nbd.2015.02.009 . 18510138 .
  60. Ludolph AC, Brettschneider J, Weishaupt JH . Amyotrophic lateral sclerosis . Current Opinion in Neurology . 25 . 5 . 530–5 . October 2012 . 22918486 . 10.1097/WCO.0b013e328356d328 .
  61. Orr HT, Zoghbi HY . Trinucleotide repeat disorders . Annual Review of Neuroscience . 30 . 1 . 575–621 . July 2007 . 17417937 . 10.1146/annurev.neuro.29.051605.113042 .
  62. Almeida B, Fernandes S, Abreu IA, Macedo-Ribeiro S . Trinucleotide repeats: a structural perspective . Frontiers in Neurology . 4 . 76 . 2013 . 23801983 . 10.3389/fneur.2013.00076 . 3687200 . free .
  63. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL . Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view . Journal of Neuropathology and Experimental Neurology . 62 . 9 . 885–98 . September 2003 . 14533778 . 10.1093/jnen/62.9.885 .
  64. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL . Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view . Journal of Neuropathology and Experimental Neurology . 62 . 9 . 885–98 . September 2003 . 14533778 . 10.1093/jnen/62.9.885 .
  65. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL . Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view . Journal of Neuropathology and Experimental Neurology . 62 . 9 . 885–98 . September 2003 . 14533778 . 10.1093/jnen/62.9.885 .
  66. Spinner NB . CADASIL: Notch signaling defect or protein accumulation problem? . The Journal of Clinical Investigation . 105 . 5 . 561–2 . March 2000 . 10712425 . 292459 . 10.1172/JCI9511 .
  67. Quinlan RA, Brenner M, Goldman JE, Messing A . GFAP and its role in Alexander disease . Experimental Cell Research . 313 . 10 . 2077–87 . June 2007 . 17498694 . 2702672 . 10.1016/j.yexcr.2007.04.004 .
  68. Ito D, Suzuki N . Seipinopathy: a novel endoplasmic reticulum stress-associated disease . Brain . 132 . Pt 1 . 8–15 . January 2009 . 18790819 . 10.1093/brain/awn216 . free .
  69. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  70. Lomas DA, Carrell RW . Serpinopathies and the conformational dementias . Nature Reviews Genetics . 3 . 10 . 759–68 . October 2002 . 12360234 . 10.1038/nrg907 . 21633779 .
  71. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  72. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  73. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  74. Mukherjee A, Soto C . Prion-Like Protein Aggregates and Type 2 Diabetes . Cold Spring Harbor Perspectives in Medicine . 7 . 5 . a024315 . May 2017 . 28159831 . 10.1101/cshperspect.a024315 . 5411686.
  75. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  76. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  77. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  78. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  79. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  80. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  81. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  82. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  83. Askanas V, Engel WK . Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition . Neurology . 66 . 2 Suppl 1 . S39-48 . January 2006 . 16432144 . 10.1212/01.wnl.0000192128.13875.1e . 24365234 .
  84. Ecroyd H, Carver JA . Crystallin proteins and amyloid fibrils . Cellular and Molecular Life Sciences . 66 . 1 . 62–81 . January 2009 . 18810322 . 10.1007/s00018-008-8327-4 . 6580402 . 2021-09-15 . 2018-07-23 . https://web.archive.org/web/20180723043635/http://ro.uow.edu.au/cgi/viewcontent.cgi?article=1967&context=scipapers . live . 11131532 .
  85. Surguchev A, Surguchov A . Conformational diseases: looking into the eyes . Brain Research Bulletin . 81 . 1 . 12–24 . January 2010 . 19808079 . 10.1016/j.brainresbull.2009.09.015 . 38832894 .
  86. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  87. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  88. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  89. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  90. Huilgol SC, Ramnarain N, Carrington P, Leigh IM, Black MM . Cytokeratins in primary cutaneous amyloidosis . The Australasian Journal of Dermatology . 39 . 2 . 81–5 . May 1998 . 9611375 . 10.1111/j.1440-0960.1998.tb01253.x . 25820489 .
  91. Janig E, Stumptner C, Fuchsbichler A, Denk H, Zatloukal K . Interaction of stress proteins with misfolded keratins . European Journal of Cell Biology . 84 . 2–3 . 329–39 . March 2005 . 15819411 . 10.1016/j.ejcb.2004.12.018 .
  92. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  93. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  94. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  95. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  96. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  97. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  98. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  99. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  100. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  101. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  102. D'Souza A, Theis JD, Vrana JA, Dogan A . Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration . Amyloid . 21 . 2 . 71–5 . June 2014 . 24446896 . 10.3109/13506129.2013.876984 . 4021035 .
  103. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P . Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines . Amyloid . 23 . 4 . 209–213 . December 2016 . 27884064 . 10.1080/13506129.2016.1257986 . free .
  104. Meng X, Clews J, Kargas V, Wang X, Ford RC . The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability . Cellular and Molecular Life Sciences . 74 . 1 . 23–38 . January 2017 . 27734094 . 10.1007/s00018-016-2386-8 . 5209436.
  105. Stuart MJ, Nagel RL . Sickle-cell disease . Lancet . 364 . 9442 . 1343–60 . 2004 . 15474138 . 10.1016/S0140-6736(04)17192-4 . 8139305 .
  106. Bernstein AM, Ritch R, Wolosin JM . Exfoliation syndrome: A disease of autophagy and LOXL1 proteopathy . Journal of Glaucoma . 27 . Supplement 1 . S44–S53 . July 2018 . 29547474 . 10.1097/IJG.0000000000000919 . 6028293.
  107. Pepys MB . Amyloidosis . Annu Rev Med . 57 . 223–241 . 2006 . 16409147 . 10.1146/annurev.med.57.121304.131243.
  108. Holtzman DM, Morris JC, Goate AM . Alzheimer's disease: the challenge of the second century . Sci Transl Med . 3 . 77 . 2011 . 21471435 . 10.1126/scitranslmed.3002369 . 3130546 . 77sr1.
  109. Pepys MB . Pathogenesis, diagnosis and treatment of systemic amyloidosis . Phil Trans R Soc Lond B . 356 . 203–211 . 2001 . 1406 . 11260801 . 10.1098/rstb.2000.0766 . 1088426.
  110. Walker LC, LeVine H 3rd . Proteopathy: the next therapeutic frontier? . Curr Opin Investig Drugs . 3 . 5 . 2002 . 12090553 . 782–7.
  111. Braczynski AK, Schulz JB, Bach JP . Vaccination strategies in tauopathies and synucleinopathies . J Neurochem . 143 . 5 . 467–488 . 2017 . 28869766 . 10.1111/jnc.14207. free .
  112. Klein WL . Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? . J Alzheimers Dis . 33 . Suppl 1 . S49-65 . 2013 . 22785404 . 10.3233/JAD-2012-129039.
  113. Badar T, D'Souza A, Hari P . Recent advances in understanding and treating immunoglobulin light chain amyloidosis . F1000Res . 2018 . 30228867 . 10.12688/f1000research.15353.1 . 7 . 6117860 . 1348 . free .
  114. Carvalho A, Rocha A, Lobato L . Liver transplantation in transthyretin amyloidosis: issues and challenges . Liver Transpl . 21 . 3 . 282–292 . 2015 . 25482846 . 10.1002/lt.24058. free .
  115. Suhr OB, Herlenius G, Friman S, Ericzon BG . Liver transplantation for hereditary transthyretin amyloidosis . Liver Transpl . 6 . 3 . 263–276 . 2000 . 10827225 . 10.1053/lv.2000.6145. free .
  116. Suhr OB, Larsson M, Ericzon BG, Wilczek HE et al . Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry . Transplantation . 100 . 2 . 373–381 . 2016 . 26656838 . 10.1097/TP.0000000000001021 . 4732012.
  117. Coelho T et al . Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis . Neurol Ther . 5 . 1 . 1–25 . 2016 . 26894299 . 10.1007/s40120-016-0040-x . 4919130.
  118. Yu D et al . Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression . Cell . 150 . 5 . 895–908 . 2012 . 22939619 . 10.1016/j.cell.2012.08.002 . 3444165.
  119. Nuvolone M, Merlini G . Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis . Expert Opin Ther Targets . 21 . 12 . 1095–1110 . 2017 . 29076382 . 10.1080/14728222.2017.1398235. 46766370 .
  120. Joseph NS, Kaufman JL . Novel Approaches for the Management of AL Amyloidosis . Curr Hematol Malig Rep . 13 . 3 . 212–219 . 2018 . 29951831 . 10.1007/s11899-018-0450-1. 49475930 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Proteinopathy".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.